四环生物(000518) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥157,012,600.06, representing a 131.69% increase compared to ¥67,767,425.29 in the same period last year[7] - Net profit attributable to shareholders was ¥10,309,269.64, a significant turnaround from a loss of ¥12,792,592.57 in Q1 2019, marking an increase of 180.59%[7] - The net profit after deducting non-recurring gains and losses was ¥11,271,079.81, compared to a loss of ¥12,906,020.79 in the previous year, reflecting a 187.33% improvement[7] - Basic and diluted earnings per share were both ¥0.0100, compared to a loss of ¥0.0124 per share in the same period last year, indicating an increase of 180.65%[7] - The weighted average return on equity was 1.67%, up from -2.16% in the previous year, showing a 3.83% improvement[7] - The company reported a significant increase in operating expenses, with management expenses rising by 56.39% to ¥27,676,474.80 from ¥17,697,559.46 due to business expansion costs[14] - The company recorded a 35149.13% increase in other operating expenses to ¥992,545.00 from ¥2,815.80, related to compensation payments to suppliers due to production suspension[14] - The operating profit for Q1 2020 was CNY 10.01 million, a significant recovery from a loss of CNY 13.98 million in Q1 2019[37] - The net profit for Q1 2020 was CNY 8.29 million, compared to a net loss of CNY 13.87 million in the previous year, indicating a turnaround in profitability[37] - The total comprehensive income for Q1 2020 was CNY 8.29 million, compared to a comprehensive loss of CNY 13.87 million in the same quarter last year[38] Cash Flow - The net cash flow from operating activities was ¥34,016,509.11, a 347.81% increase from a negative cash flow of ¥13,726,806.75 in Q1 2019[7] - Total cash inflow from operating activities was ¥123,976,196.16, while cash outflow was ¥89,959,687.05, resulting in a net cash inflow[45] - The company reported a net cash outflow from investing activities of ¥573,681.20, compared to a larger outflow of ¥1,287,510.00 in the previous year[45] - Cash flow from financing activities resulted in a net outflow of ¥54,299,308.25, a significant increase from the previous year's outflow of ¥1,278,750.01[46] - The total cash inflow from financing activities was ¥0.00, indicating no new borrowings or investments received during the quarter[46] - The company's cash flow from operating activities was CNY 123.92 million, an increase from CNY 88.87 million in the previous year, reflecting improved cash generation[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥855,605,053.95, a decrease of 6.58% from ¥915,826,035.12 at the end of the previous year[7] - The total liabilities as of March 31, 2020, were CNY 119,464,910.61, showing a minor increase from CNY 119,389,765.98 at the end of 2019[33] - The company's total equity as of March 31, 2020, was CNY 595,759,445.61, a slight decrease from CNY 596,611,644.80 at the end of 2019[33] - Current liabilities reached CNY 253,774,281.05, with accounts payable at CNY 63,351,021.26[53] - Owner's equity totaled CNY 660,314,269.99, with total liabilities at CNY 255,511,765.13[54] Operating Performance - Operating revenue increased by 131.69% to ¥157,012,600.06 compared to ¥67,767,425.29, driven by increased sales in Guangxi Intercontinental[14] - Operating costs surged by 479.83% to ¥81,342,214.91 from ¥14,028,585.20, with material sales outpacing pharmaceutical sales but at a lower gross margin[14] - Total operating revenue for Q1 2020 was CNY 157,012,600.06, a significant increase from CNY 67,767,425.29 in the same period last year, representing a growth of approximately 131.5%[35] - Total operating costs for Q1 2020 amounted to CNY 144,823,734.07, compared to CNY 81,707,984.23 in Q1 2019, indicating an increase of about 77.2%[36] Research and Development - Research and development expenses decreased by 70.59% to ¥2,553,049.60 from ¥8,681,804.90 due to reduced outsourced R&D costs[14] - Research and development expenses decreased to CNY 2,553,049.60 in Q1 2020 from CNY 8,681,804.90 in the same period last year, reflecting a reduction of approximately 70.7%[36] - The company has a development expenditure of CNY 15,000,000.00, indicating ongoing investment in R&D[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 124,339[10] - Net assets attributable to shareholders increased by 1.68% to ¥623,837,698.34 from ¥613,528,428.70 at the end of the previous year[7] Miscellaneous - The company did not report any revenue from new product launches or technological advancements during this quarter[41] - There were no significant mergers or acquisitions reported in the first quarter of 2020[41] - The company has not provided specific guidance for future performance or market expansion strategies in this report[41] - The report indicates that the new revenue and leasing standards were not applicable for the first quarter[58] - The company has not undergone an audit for the first quarter report[59]